AbbVie Stock Forecast for 2023 - 2025 - 2030

Updated on 04/01/2023

Stock Rating
10
Price Target
$165.00
Consensus
Outperform
Upside
3.54%
Analysts
16
Stock Rating
10
Upside
3.54%
Analysts
16
Price Target
$165.00

AbbVie Stock Forecast and Price Target

AbbVie's stock is projected to advance by 3.54% from the previous closing price if it reaches the average target of $165.00 by the year's end, as sixteen reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $200.00 and a low-end estimate of $120.00. Even if you are not interested in ABBV stock, it is still imperative to be aware of its competitors.

$165.00

3.54% Upside

Outperform
Outperform

AbbVie Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, AbbVie's Price has grown, increasing from $91.55 to $130.05 – an increase of 42.06%. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. Over the next eight years, the pros' prediction is Fair Valueof $146.64, which would mean a eight-year growth forecast of 12.76%.

2023 Fair Value Forecast
$122.98
2024 Fair Value Forecast
$122.78
2025 Fair Value Forecast
$133.22
2026 Fair Value Forecast
$140.19
2027 Fair Value Forecast
$143.97
2028 Fair Value Forecast
$148.89
2029 Fair Value Forecast
$149.30
2030 Fair Value Forecast
$146.64
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 10
$154.95 $181.05 16.49%
LLY Stock Forecast Eli Lilly and Outperform 16
$343.42 $333.19 16.48%
AZN Stock Forecast AstraZeneca PLC Outperform 8
£11.25k £153.20 -98.61%
OR Stock Forecast L'Oréal Outperform 10
358.60€ 366.71€ 3.88%
ABT Stock Forecast Abbott Laboratories Outperform 10
$101.26 $121.44 23.44%

AbbVie Revenue Forecast for 2023 - 2025 - 2030

In the last two years, AbbVie's Revenue has grown, increasing from $33.27B to $56.20B – an increase of 68.93%. According to 19 major analysts, AbbVie's Revenue will fall by 0.48% in the next year, reaching $55.93B. Over the next eight years, the pros' prediction is Revenueof $63.93B, which would mean a eight-year growth forecast of 13.76%.

2023 Rev Forecast
$55.93B
2024 Rev Forecast
$56.47B
2025 Rev Forecast
$58.95B
2026 Rev Forecast
$61.80B
2027 Rev Forecast
$63.60B
2028 Rev Forecast
$65.34B
2029 Rev Forecast
$65.24B
2030 Rev Forecast
$63.93B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$69.31 $80.99 19.75%
AMGN Stock Forecast Amgen Inc Hold 7
$241.75 $268.00 14.99%
ABI Stock Forecast Anheuser-Busch InBev SA/NV Outperform 5
57.44€ 68.16€ 16.68%

AbbVie Dividend per Share Forecast for 2023 - 2025 - 2030

AbbVie's Dividend per Share has increased by 20.96% In the last two years, going from $4.39 to $5.31. In the next year, analysts expect Dividend per Share to reach $6.00 – an increase of 12.99%. For the next eight years, the forecast is for Dividend per Share to grow by 15.44%.

2023 DPS Forecast
$6.00
2024 DPS Forecast
$6.17
2025 DPS Forecast
$6.50
2026 DPS Forecast
$6.93
2027 DPS Forecast
$6.79
2028 DPS Forecast
$6.13
2029 DPS Forecast
$6.13
2030 DPS Forecast
$6.13
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GILD Stock Forecast Gilead Sciences Inc Outperform 11
$83.00 $87.30 6.02%
BDX Stock Forecast Becton, Dickinson and Outperform 17
$247.48 $268.00 11.12%
MMM Stock Forecast 3M Hold 16
$105.08 $147.79 13.72%

AbbVie Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, AbbVie's Free Cash Flow has grown by 72.17%, from $12.77B to $21.99B. For the next year, analysts are expecting Free Cash Flow to reach $23.54B – an increase of 7.05%. Over the next eight years, experts predict that Free Cash Flow will grow by 26.59%.

2023 FCF Forecast
$23.54B
2024 FCF Forecast
$22.89B
2025 FCF Forecast
$24.83B
2026 FCF Forecast
$26.28B
2027 FCF Forecast
$27.04B
2028 FCF Forecast
$27.44B
2029 FCF Forecast
$27.33B
2030 FCF Forecast
$27.84B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
GSK Stock Forecast GSK Hold 16
£1.43k £16.95 -98.87%
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.07k ¥0.00 35.30%
BAYN Stock Forecast Bayer Outperform 7
58.72€ 74.54€ 28.58%

AbbVie Net Income Forecast for 2023 - 2025 - 2030

In the last two years, AbbVie's Net Income has grown, increasing from $7.88B to $11.54B – a growth of 46.43%. The next year looks promising for AbbVie, with analysts predicting Net Income of $21.29B – an increase of 84.47%. Over the next eight years, experts anticipate that AbbVie's Net Income will grow at a rate of 106.60%.

2023 NI Forecast
$21.29B
2024 NI Forecast
$21.25B
2025 NI Forecast
$22.87B
2026 NI Forecast
$23.91B
2027 NI Forecast
$24.17B
2028 NI Forecast
$24.72B
2029 NI Forecast
$24.54B
2030 NI Forecast
$23.85B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.31k ¥0.00 36.03%
BIIB Stock Forecast Biogen Inc Outperform 11
$278.03 $322.44 16.89%
ALC Stock Forecast Alcon Outperform 15
CHF66.18 CHF0.00 30.51%

AbbVie EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, AbbVie's EBITDA has grown from $16.26B to $28.05B – a 72.47% increase. 6 analysts predict AbbVie's EBITDA will decrease by 1.26% in the next year, reaching $27.70B. Over the next eight years, the forecast is for EBITDA to grow by 13.19%.

2023 EBITDA Forecast
$27.70B
2024 EBITDA Forecast
$27.42B
2025 EBITDA Forecast
$28.53B
2026 EBITDA Forecast
$31.22B
2027 EBITDA Forecast
$31.94B
2028 EBITDA Forecast
$33.00B
2029 EBITDA Forecast
$32.39B
2030 EBITDA Forecast
$31.75B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
HZNP Stock Forecast Horizon Therapeutics Public Buy 16
$113.00 $0.00 23.89%
GMAB Stock Forecast Genmab A/S Outperform 16
kr3.00k kr2.84k -8.24%
BEI Stock Forecast Beiersdorf Outperform 17
119.95€ 110.36€ -4.13%

AbbVie EBIT Forecast for 2023 - 2025 - 2030

In the last two years, AbbVie's EBIT has grown by 37.07%, rising from $14.25B to $19.53B. For next year, analysts predict EBIT of $26.78B, which would mean an increase of 37.11%. Over the next eight years, experts predict that AbbVie's EBIT will grow at a rate of 60.72%.

2023 EBIT Forecast
$26.78B
2024 EBIT Forecast
$26.64B
2025 EBIT Forecast
$28.40B
2026 EBIT Forecast
$30.12B
2027 EBIT Forecast
$31.25B
2028 EBIT Forecast
$32.46B
2029 EBIT Forecast
$32.42B
2030 EBIT Forecast
$31.39B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4503 Stock Forecast Astellas Pharma Outperform 18
¥1.92k ¥0.00 24.74%
BAX Stock Forecast Baxter International Inc Outperform 17
$40.56 $60.73 43.00%
BMRN Stock Forecast BioMarin Pharmaceutical Outperform 10
$97.27 $115.45 23.37%

AbbVie EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, AbbVie's EPS has grown, increasing from $8.94 to $12.70 – an increase of 42.06%. According to 23 major analysts, AbbVie's EPS will fall by 5.43% in the next year, reaching $12.01. Over the next eight years, the pros' prediction is EPSof $14.32, which would mean a eight-year growth forecast of 12.76%.

2023 EPS Forecast
$12.01
2024 EPS Forecast
$11.99
2025 EPS Forecast
$13.01
2026 EPS Forecast
$13.69
2027 EPS Forecast
$14.06
2028 EPS Forecast
$14.54
2029 EPS Forecast
$14.58
2030 EPS Forecast
$14.32
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
INCY Stock Forecast Incyte Outperform 9
$72.28 $88.18 18.98%
4452 Stock Forecast Kao Outperform 18
¥5.11k ¥0.00 17.53%
4523 Stock Forecast Eisai Hold 18
¥8.15k ¥0.00 -18.99%